🇺🇸 FDA
Patent

US 11530220

Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR

granted A61KA61K45/06A61P

Quick answer

US patent 11530220 (Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR) held by IDEAYA Biosciences, Inc. expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
IDEAYA Biosciences, Inc.
Grant date
Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K45/06, A61P, A61P35/00